Serrano, César
Mariño-Enríquez, Adrián
Tao, Derrick L.
Ketzer, Julia
Eilers, Grant
Zhu, Meijun
Yu, Channing
Mannan, Aristotle M.
Rubin, Brian P.
Demetri, George D.
Raut, Chandrajit P.
Presnell, Ajia
McKinley, Arin
Heinrich, Michael C. http://orcid.org/0000-0003-3790-0478
Czaplinski, Jeffrey T.
Sicinska, Ewa
Bauer, Sebastian
George, Suzanne
Fletcher, Jonathan A.
Article History
Received: 17 July 2018
Revised: 28 September 2018
Accepted: 22 October 2018
First Online: 22 February 2019
Change Date: 23 May 2019
Change Type: Correction
Change Details: The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following:M.C.H. has the following competing interests to declare: Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare.The authors apologise for any convenience this may have caused.
Competing interests
: The authors declare no competing interests.
: All the conclusions reached by the authors are supported by available main and supplementary tables and figures.
: GIST patients’ samples were obtained for these studies from the phase II trial of single-agent regorafenib in GIST.<sup>23</sup> The study was conducted in accordance with the ethical principles originating from the Declaration of Helsinki and Good Clinical Practice. All patients provided written informed consent before enrolment onto the study. The protocol was reviewed and approved by the institutional review board at all participating sites. PDX experiments were undertaken as previously described.<sup>45</sup> All procedures were carried out according to protocols approved by the Institutional Animal Care and Use Committee of the Dana-Farber Cancer Institute.
: This work was supported in part by an ASCO Young Investigator Award (CS), a Spanish Society of Medical Oncology Translational Award (CS), Río Hortega-ISCIII CM14/00241 (CS) FERO Foundation (CS), US National Institutes of Health grants 1P50CA127003 (GDD, ES, JAF), 1P50CA168512 (JAF, AME), GIST Cancer Research Fund (JAF, MCH), Life Raft Group (JAF, MCH, SB), V Foundation Translational Grant (MCH), VA Merit Review Award (2I01BX000338–05) (MCH) and the Deutsche Krebshilfe (SB). CS acknowledges to the Cellex Foundation for providing facilities and equipment.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).